Chronic PainH-PassionNCT07740681
Human Pain Atlas for Sensory Neurons
An observational study of Chronic Pain, run by King's College Hospital NHS Trust.
Trial summary
This study aims to improve our understanding of how the nerves that detect and transmit pain signals work in humans. Chronic pain affects millions of people worldwide and can be difficult to treat because the biological mechanisms underlying pain are not yet fully understood. Read more about this study
- Who is it for?
- Ages 18 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Chronic Pain
- What is being tested?
- Microneurography
- How many people
- 200 participants
- Where
- No sites listed yet
- Study dates
- Sep 2026to Sep 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: 100 patients with ongoing neuropathic pain in the context of a possible small fibre neuropathy or C-fibre dysfunction. 100 healthy volunteers.
Who may be able to join
- Between 18 and 75 years of age.
- Male and female.
- In the capacity to understand and sign an Informed Consent Form.
- Willing and able to comply with scheduled visits and study procedures.
- Criteria for chronic pain participants:
- Ongoing neuropathic pain in the context of a possible small fibre neuropathy or C-fibre dysfunction
- Criteria for healthy participants:
- Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history and a full physical examination.
Who cannot join
- Previous diagnosis of an established autoimmune condition or dermatological conditions affecting skin afferents (e.g. psoriasis, lupus, vitiligo, dermatitis…).
- Application of local anaesthetics or steroid injections within 35 days prior to the microneurography visit.
- Unsuitable anatomy of the superficial peroneal nerve (i.e. nerve cannot be seen or palpated at the dorsum of the foot/ankle)
- Infection, disease (dermatologic or vascular), ongoing pain or recent trauma or surgery that may affect study assessments.
- Current use of anticoagulant therapy.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
Jordi Serra, MD contact
About this study
Official title: Human Pain Atlas for Sensory Neurons: A Multimodal Strategy of Investigation of Neuropathic Pain MechanismsH-Passion
This study aims to improve our understanding of how the nerves that detect and transmit pain signals work in humans. Chronic pain affects millions of people worldwide and can be difficult to treat because the biological mechanisms underlying pain are not yet fully understood. By gaining a better understanding of the human pain system, this research may help guide the development of more effective and personalised treatments for chronic pain in the future.
The study will investigate sensory neurons, which are specialised nerve cells that detect sensations such as touch, temperature, and injury. We will examine both how these nerve cells respond to stimulation and the genes they express. By linking the activity of individual nerve cells with their molecular characteristics, we hope to identify specific types of sensory neurons that may contribute to chronic pain conditions.
Read more
To achieve this, we will use a technique called microneurography. This involves inserting a very fine recording electrode into a peripheral nerve to measure the activity of individual nerve fibres directly in the body. These recordings will be performed in healthy volunteers and in patients. The information obtained will be combined with laboratory-based studies conducted by collaborators in Germany and France, allowing us to relate detailed biological findings to the experience of pain in humans.
The results of this research will provide a detailed map of the human sensory nervous system and improve our understanding of how pain-signalling neurons function in health and disease. This knowledge may support the development of future treatments for chronic pain.
Read the detailed description
Chronic pain remains a major challenge for modern healthcare, with limited effective treatments. Neuropathic pain is linked to increased activity in pain-relevant subgroups of the sensory neurons located in the dorsal root ganglia. One of the key reasons for the lack of effective treatments is the incomplete understanding of the neurobiological mechanisms underlying chronic neuropathic pain, particularly in the context of human-specific pain pathways. While animal models have provided valuable insights, they do not fully recapitulate human pain experiences due to significant species differences, especially in the structure and function of sensory neurons, which has led to significant translational hurdles in the development of new pain therapies.
In recent years, research has made significant strides in creating transcriptomic atlases of sensory neurons. These atlases provide valuable insights into the genetic and molecular landscape of human nociceptors. However, they are often limited by the inability to fully link these molecular findings with functional data, especially in the context of chronic pain. Additionally, many of these atlases are based on limited data from healthy donors, thus not fully capturing the heterogeneity found in pain-related sensory neurons. While recent efforts have begun to address these gaps by exploring the relationship between transcriptomic data and sensory neuron function, the field still faces major limitations. One key issue is the identification of pain-related sensory neurons, which can exhibit diverse activity patterns that may not align with current classifications. Moreover, existing atlases lack the integration of long-read RNA sequencing, which is crucial for identifying splice variants and other molecular nuances that may be critical for understanding pain pathways.
This consortium will leverage state-of-the-art technologies like Patch-Seq, single-cell long-read RNA sequencing, and microneurography to build a comprehensive atlas of human sensory neurons involved in pain processing. This approach will integrate high-resolution transcriptomic data with functional information, which is essential for addressing the current gap in our understanding of pain sensory neurons. One of the main challenges in the field has been the difficulty of linking molecular data to function, particularly when it comes to pain subtypes. The proposed project's approach will address this challenge by incorporating multiple techniques, which are expected to produce a more nuanced and clinically relevant understanding of sensory neuron diversity. Despite the promising progress made in creating human Dorsal Root Ganglia (DRG) atlases, the identification of pain-related neurons remains a significant challenge. There are concerns that certain pain-related neurons may not be captured using standard stimulation protocols. This is especially true for neurons whose activity patterns differ from known models. To address this, the proposal will combine detailed in-vitro and in-vivo electrophysiological recordings with advanced RNA sequencing to characterise sensory neurons, using stimulation protocols that are tailored to capture a wider range of neuronal subtypes. We will develop subtype-specific stimulation paradigms for in vivo microneurography as another innovative aspect of this proposal. This method could dramatically enhance our ability to stratify patients based on the specific sensory neuron subtypes contributing to their pain, thus facilitating personalised approaches to pain management. Moreover, integrating human tissue samples from both healthy and chronic pain patients is a significant step forward in ensuring that findings are potentially validated in a clinical scenario. This approach not only makes the project more clinically relevant but also enhances its translational potential since there is still a huge demand for novel pharmacological targets for pain treatment. With our consortium, we expect to identify novel sensory neuron-subtype specific transcript isoforms as biomarkers and druggable targets for e.g. gene therapeutic approaches like ASOs (antisense-oligonucleotides). By selectively targeting transcript isoforms that are specific to sensory neurons of chronic pain patients, ASO-mediated splice modulation that could change the amount of a "pathological" transcript isoform will be investigated in future follow-up studies as "genetic pain killers".
This project aims to fill the critical gap in the current understanding of pain-related sensory neurons by generating a comprehensive, multidimensional atlas of human sensory neurons. By combining the latest advances in transcriptomics, electrophysiology, and microneurography, the proposal promises to offer new insights into the molecular and functional diversity of sensory neurons involved in chronic pain. This integrated approach not only addresses existing knowledge gaps but also provides a solid foundation for future therapeutic advancements in pain management.
The main objective is to elucidate the molecular and functional mechanisms underlying chronic neuropathic pain by building the first comprehensive, multimodal sensory neuron atlas based on human DRG material. This dataset will integrate electrophysiology, gene expression (including long-read single-cell RNA sequencing), and in vivo microneurography data in humans, ultimately identifying novel molecular and electrophysiological biomarkers and neuronal subtypes involved in pain processing.
The UK organisation will be responsible for obtaining microneurography recordings from human participants, including patients suffering from chronic pain conditions and healthy volunteers, to refine neuron subtype classifications and develop new stimulation protocols. These will be used for refinement of the functional characterisation of neurons in the Patch-Seq Pipeline. This will end in a multimodal atlas of sensory neurons, with integration of long-read transcriptomic data with electrophysiological properties from Patch-seq and in vivo microneurography to classify pain-relevant neuronal subtypes.
- Conditions
- Chronic Pain
- Being tested
- Microneurography
- Keywords
- Chronic pain, Microneurography, Human Sensory Atlas
- Medical subject headings
- Chronic Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MicroneurographyDiagnostic test
Electrophysiological technique that can record action potentials from individual peripheral nerve axons in humans. The test will be used to identify/rule out small nerve fibre dysfunction and measures of axonal excitability.
| Study group | Role | What they receive |
|---|---|---|
| Chronic pain | Participants suffering from chronic neuropathic pain. Receives: Diagnostic Test: Microneurography | |
| Healthy volunteers | Healthy volunteers, defined by no clinically relevant abnormalities identified by a detailed medical history and a full physical examination. Receives: Diagnostic Test: Microneurography |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessment of molecular and functional mechanisms underlying chronic neuropathic pain
To refine neuron subtype classifications by developing new stimulation paradigms for precise classification of neuronal subgroups involved in chronic pain. To specify underlying mechanisms of the unmyelinated axonal membrane excitability.
Measured: Day 1
Secondary outcomes (2)
To bridge basic and clinical research
To integrate preclinical data (Patch-seq, long-read sequencing) with clinical data (microneurography) to accelerate the translation of research into personalised pain management strategies.
Measured: Day 1
Chronic pain database
To build a database of 100 patients with neuropathic pain due to small fibre neuropathy using the pre-identified electrophysiological profiles.
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jul 2026
- Study startSep 2026 (estimated)
- Primary completionSep 2028 (estimated)
- Study completionSep 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic PainStudies of the same condition, open and under way.
- More trials run by King's College Hospital NHS TrustThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- King's College Hospital NHS Trust
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07740681
- Sponsor's protocol ID
- 370701
- Acronym
- H-Passion
- Status last verified
- Jul 2026
- First submitted
- 13 Jul 2026
- Last updated
- 31 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Human Pain Atlas for Sensory Neurons: A Multimodal Strategy of Investigation of Neuropathic Pain MechanismsH-Passion
- ClinicalTrials.gov ID
- NCT07740681
- Acronym / sponsor ID
- H-Passion / 370701
- Conditions
- Chronic Pain
- Keywords
- Chronic pain, Microneurography, Human Sensory Atlas
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- King's College Hospital NHS TrustUniversity, hospital or other
- Study start
- Sep 2026 (estimated)
- Primary completion
- Sep 2028 (estimated)
- Study completion
- Sep 2029 (estimated)
- First posted
- 31 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to improve our understanding of how the nerves that detect and transmit pain signals work in humans. Chronic pain affects millions of people worldwide and can be difficult to treat because the biological mechanisms underlying pain are not yet fully understood. By gaining a better understanding of the human pain system, this research may help guide the development of more effective and personalised treatments for chronic pain in the future.
The study will investigate sensory neurons, which are specialised nerve cells that detect sensations such as touch, temperature, and injury. We will examine both how these nerve cells respond to stimulation and the genes they express. By linking the activity of individual nerve cells with their molecular characteristics, we hope to identify specific types of sensory neurons that may contribute to chronic pain conditions.
To achieve this, we will use a technique called microneurography. This involves inserting a very fine recording electrode into a peripheral nerve to measure the activity of individual nerve fibres directly in the body. These recordings will be performed in healthy volunteers and in patients. The information obtained will be combined with laboratory-based studies conducted by collaborators in Germany and France, allowing us to relate detailed biological findings to the experience of pain in humans.
The results of this research will provide a detailed map of the human sensory nervous system and improve our understanding of how pain-signalling neurons function in health and disease. This knowledge may support the development of future treatments for chronic pain.
Detailed description
Chronic pain remains a major challenge for modern healthcare, with limited effective treatments. Neuropathic pain is linked to increased activity in pain-relevant subgroups of the sensory neurons located in the dorsal root ganglia. One of the key reasons for the lack of effective treatments is the incomplete understanding of the neurobiological mechanisms underlying chronic neuropathic pain, particularly in the context of human-specific pain pathways. While animal models have provided valuable insights, they do not fully recapitulate human pain experiences due to significant species differences, especially in the structure and function of sensory neurons, which has led to significant translational hurdles in the development of new pain therapies.
In recent years, research has made significant strides in creating transcriptomic atlases of sensory neurons. These atlases provide valuable insights into the genetic and molecular landscape of human nociceptors. However, they are often limited by the inability to fully link these molecular findings with functional data, especially in the context of chronic pain. Additionally, many of these atlases are based on limited data from healthy donors, thus not fully capturing the heterogeneity found in pain-related sensory neurons. While recent efforts have begun to address these gaps by exploring the relationship between transcriptomic data and sensory neuron function, the field still faces major limitations. One key issue is the identification of pain-related sensory neurons, which can exhibit diverse activity patterns that may not align with current classifications. Moreover, existing atlases lack the integration of long-read RNA sequencing, which is crucial for identifying splice variants and other molecular nuances that may be critical for understanding pain pathways.
This consortium will leverage state-of-the-art technologies like Patch-Seq, single-cell long-read RNA sequencing, and microneurography to build a comprehensive atlas of human sensory neurons involved in pain processing. This approach will integrate high-resolution transcriptomic data with functional information, which is essential for addressing the current gap in our understanding of pain sensory neurons. One of the main challenges in the field has been the difficulty of linking molecular data to function, particularly when it comes to pain subtypes. The proposed project's approach will address this challenge by incorporating multiple techniques, which are expected to produce a more nuanced and clinically relevant understanding of sensory neuron diversity. Despite the promising progress made in creating human Dorsal Root Ganglia (DRG) atlases, the identification of pain-related neurons remains a significant challenge. There are concerns that certain pain-related neurons may not be captured using standard stimulation protocols. This is especially true for neurons whose activity patterns differ from known models. To address this, the proposal will combine detailed in-vitro and in-vivo electrophysiological recordings with advanced RNA sequencing to characterise sensory neurons, using stimulation protocols that are tailored to capture a wider range of neuronal subtypes. We will develop subtype-specific stimulation paradigms for in vivo microneurography as another innovative aspect of this proposal. This method could dramatically enhance our ability to stratify patients based on the specific sensory neuron subtypes contributing to their pain, thus facilitating personalised approaches to pain management. Moreover, integrating human tissue samples from both healthy and chronic pain patients is a significant step forward in ensuring that findings are potentially validated in a clinical scenario. This approach not only makes the project more clinically relevant but also enhances its translational potential since there is still a huge demand for novel pharmacological targets for pain treatment. With our consortium, we expect to identify novel sensory neuron-subtype specific transcript isoforms as biomarkers and druggable targets for e.g. gene therapeutic approaches like ASOs (antisense-oligonucleotides). By selectively targeting transcript isoforms that are specific to sensory neurons of chronic pain patients, ASO-mediated splice modulation that could change the amount of a "pathological" transcript isoform will be investigated in future follow-up studies as "genetic pain killers".
This project aims to fill the critical gap in the current understanding of pain-related sensory neurons by generating a comprehensive, multidimensional atlas of human sensory neurons. By combining the latest advances in transcriptomics, electrophysiology, and microneurography, the proposal promises to offer new insights into the molecular and functional diversity of sensory neurons involved in chronic pain. This integrated approach not only addresses existing knowledge gaps but also provides a solid foundation for future therapeutic advancements in pain management.
The main objective is to elucidate the molecular and functional mechanisms underlying chronic neuropathic pain by building the first comprehensive, multimodal sensory neuron atlas based on human DRG material. This dataset will integrate electrophysiology, gene expression (including long-read single-cell RNA sequencing), and in vivo microneurography data in humans, ultimately identifying novel molecular and electrophysiological biomarkers and neuronal subtypes involved in pain processing.
The UK organisation will be responsible for obtaining microneurography recordings from human participants, including patients suffering from chronic pain conditions and healthy volunteers, to refine neuron subtype classifications and develop new stimulation protocols. These will be used for refinement of the functional characterisation of neurons in the Patch-Seq Pipeline. This will end in a multimodal atlas of sensory neurons, with integration of long-read transcriptomic data with electrophysiological properties from Patch-seq and in vivo microneurography to classify pain-relevant neuronal subtypes.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Chronic pain | – | Diagnostic Test: MicroneurographyParticipants suffering from chronic neuropathic pain. |
| Healthy volunteers | – | Diagnostic Test: MicroneurographyHealthy volunteers, defined by no clinically relevant abnormalities identified by a detailed medical history and a full physical examination. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- 100 patients with ongoing neuropathic pain in the context of a possible small fibre neuropathy or C-fibre dysfunction. 100 healthy volunteers.
Key inclusion criteria (8 listed)
- Between 18 and 75 years of age.
- Male and female.
- In the capacity to understand and sign an Informed Consent Form.
- Willing and able to comply with scheduled visits and study procedures.
- Criteria for chronic pain participants:
Key exclusion criteria (5 listed)
- Previous diagnosis of an established autoimmune condition or dermatological conditions affecting skin afferents (e.g. psoriasis, lupus, vitiligo, dermatitis…).
- Application of local anaesthetics or steroid injections within 35 days prior to the microneurography visit.
- Unsuitable anatomy of the superficial peroneal nerve (i.e. nerve cannot be seen or palpated at the dorsum of the foot/ankle)
- Infection, disease (dermatologic or vascular), ongoing pain or recent trauma or surgery that may affect study assessments.
- Current use of anticoagulant therapy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MicroneurographyElectrophysiological technique that can record action potentials from individual peripheral nerve axons in humans. The test will be used to identify/rule out small nerve fibre dysfunction and measures of axonal excitability. | Diagnostic test | Chronic pain, Healthy volunteers |
Primary outcome
Assessment of molecular and functional mechanisms underlying chronic neuropathic pain
Time frame: Day 1
To refine neuron subtype classifications by developing new stimulation paradigms for precise classification of neuronal subgroups involved in chronic pain. To specify underlying mechanisms of the unmyelinated axonal membrane excitability.
2 secondary outcomes
To bridge basic and clinical research
Time frame: Day 1
Chronic pain database
Time frame: Day 1
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Jul 2026.
Related trials for Chronic Pain
Recruiting
Empowered Relief® for Cancer Survivors With Chronic Pain
Chronic Pain Due to Cancer, Pain Catastrophizing
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Effect of Lumbar Stabilization Exercises With and Without YTWL (Scapular Stabilization Exercises) on Reducing Chronic Low Back Pain and Related Disability. A Randomized Clinical Trial,
Chronic Non Specific Mechanical Low Back Pain
Not yet recruiting
Comparing Non-Medicine Strategies for Improving Low Back Pain
Chronic Low-back Pain (cLBP), High-Impact Chronic Pain (HICP)
Not yet recruiting
Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain
Breast Cancer, Postoperative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jordi Serra, MD contact
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Pain, run by King's College Hospital NHS Trust.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 31 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ana Ribeiro, MSc (+447768974020, anaribeiro@nhs.net), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessment of molecular and functional mechanisms underlying chronic neuropathic pain (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jul 2026.